|  | **Analysis Dataset -- Germany**(ZfKD data from 11 regions) | | **Validation Dataset -- United States**(SEER data from 17 regions) | |
| --- | --- | --- | --- | --- |
|  | Female | Male | Female | Male |
| Age-standardized incidence rate of lung cancer | | | | |
| ASIR 2002 - 2013 | <img src="data:image/png;base64," style="height:70px;"> | <img src="data:image/png;base64," style="height:70px;"> | <img src="data:image/png;base64," style="height:70px;"> | <img src="data:image/png;base64," style="height:70px;"> |
| ASIR in 2013 [per 100,000] (95% CI) | 16.4 (16.0 to 16.9) | 34.1 (33.5 to 34.7) | 12.0 (11.9 to 12.1) | 14.9 (14.8 to 15.0) |
| Patients with primary LC (with at least 6 months of survival)*a* | | | | |
| n (% of Total) | 43,175 (31.8%) | 92,397 (68.2%) | 133,401 (50.6%) | 130,421 (49.4%) |
| Age at diagnosis of LC | | | | |
| 30 - 49 | 4,065 (9.4%) | 5,373 (5.8%) | 8,653 (6.5%) | 7,496 (5.7%) |
| 50 - 59 | 9,990 (23.1%) | 17,717 (19.2%) | 23,306 (17.5%) | 24,390 (18.7%) |
| 60 - 69 | 13,996 (32.4%) | 33,674 (36.4%) | 39,836 (29.9%) | 42,210 (32.4%) |
| 70 - 79 | 11,380 (26.4%) | 28,998 (31.4%) | 40,486 (30.3%) | 39,071 (30.0%) |
| 80+ | 3,744 (8.7%) | 6,635 (7.2%) | 21,120 (15.8%) | 17,254 (13.2%) |
| Median age [years] | 65.6 | 67.2 | 68.5 | 68.5 |
| Year of diagnosis of LC | | | | |
| 2002 - 2005 | 11,931 (27.6%) | 30,235 (32.7%) | 43,382 (32.5%) | 44,697 (34.3%) |
| 2006 - 2009 | 14,712 (34.1%) | 31,499 (34.1%) | 44,922 (33.7%) | 43,957 (33.7%) |
| 2010 - 2013 | 16,532 (38.3%) | 30,663 (33.2%) | 45,097 (33.8%) | 41,767 (32.0%) |
| Histology of LC | | | | |
| Squamous cell carcinoma (SCC) | 6,886 (15.9%) | 31,858 (34.5%) | 21,280 (16.0%) | 33,214 (25.5%) |
| Adenocarcinoma (AC) | 19,327 (44.8%) | 28,626 (31.0%) | 59,518 (44.6%) | 47,065 (36.1%) |
| Small cell carcinoma (SCLC) | 8,530 (19.8%) | 15,795 (17.1%) | 17,307 (13.0%) | 15,717 (12.1%) |
| Large cell carcinoma (LCC) | 2,616 (6.1%) | 5,652 (6.1%) | 7,343 (5.5%) | 7,667 (5.9%) |
| Other & unspecified (O&U) | 5,816 (13.5%) | 10,466 (11.3%) | 27,953 (21.0%) | 26,758 (20.5%) |
| Person-years at risk | | | | |
| Mean follow-up [months] | 32.7 | 29.9 | 34.3 | 29.9 |
| Sum of PYAR | 117496 | 230346 | 380943 | 324648 |
| Patient status | | | | |
| SPLC developed | 154 (0.4%) | 388 (0.4%) | 3,775 (2.8%) | 3,102 (2.4%) |
| other SPC developed | 1,337 (3.1%) | 3,416 (3.7%) | 4,188 (3.1%) | 4,836 (3.7%) |
| dead after LC | 29,300 (67.9%) | 68,582 (74.2%) | 90,026 (67.5%) | 96,168 (73.7%) |
| no event until end of follow-up | 12,384 (28.7%) | 20,011 (21.7%) | 35,412 (26.5%) | 26,315 (20.2%) |
| Absolute incidence rate of SPC | | | | |
| SPLC IR [per 100,000 PYAR] (95% CI) | 131.1 (111.2 to 153.5) | 168.4 (152.1 to 186.1) | 991.0 (959.6 to 1023.1) | 955.5 (922.2 to 989.7) |
| Other SPC IR [per 100,000 PYAR] (95% CI) | 1137.9 (1077.7 to 1200.6) | 1483.0 (1433.7 to 1533.6) | 1099.4 (1066.3 to 1133.2) | 1489.6 (1447.9 to 1532.2) |
| *a*after exclusion by age and unusual histology | | | | |
| ASIR age-standardized incidence rate based on the World Standard Population 1960; DCO death-certificate only; IR incidence rate; LC primary lung cancer; PYAR person-years at risk; SPC second primary cancer; SPLC second primary lung cancer | | | | |